A major goal of the World Marrow Donor Association (WMDA) is to foster international transplants of hematopoietic stem cells through the establishment of guidelines and recommendations in this field. In this tradition, this study defines a comprehensive framework for HLA matching programs, which use intricate algorithms to rapidly select potential donors for a patient from a database and to present these donors in a prioritized list. Starting with the comparison of single HLA markers of the donor and the patient possibly obtained using different testing methodologies at different resolutions, the more complex matching of loci and phenotypes is inductively built up. The consensus of this international collaborative group describes the state of the art in the field and points out many important design options compatible with the best practice. This should help existing registries to review and validate the most critical part of their IT systems and newly created donor registries around the world to tackle one of their real challenges.
Introduction
One of the major challenges in setting up a registry of volunteer hematopoietic stem cell donors and/or umbilical cord blood units (CBUs) is the development of a reliable and efficient matching algorithm. The objective of such a procedure is to present a limited list of donor and/or CBU candidates, in which those most likely to be an optimal stem cell source for the patient are sorted to the top of the list. Selection and sorting criteria are usually based on relationships among HLA assignments and may also consider the transplant protocol and the overall demographics of donors. The underlying general rules are typically set up by experts but it is also common to provide sorting and/or filtering options that can be applied by experienced transplant centers according to the need of each individual patient.
This study defines a framework for HLA-based matching to serve as a guide for the world-wide registry/cord blood bank communities. In a bottom-up approach, the comparison of the attributes of the donor with those of the recipient is discussed on the level of individual HLA Ags/alleles, then HLA single-locus phenotypes and eventually HLA multi-locus phenotypes. This study is primarily intended for the joint reading of medical experts and their software engineers who are working together to design or improve a matching software. Very specific issues and questions that a software engineer will inevitably be confronted with when implementing a matching algorithm are provided in the technical Appendix (Supplementary file available online). The framework presented below was approved by the Board of the World Marrow Donor Association (WMDA) in March 2009. Allele names used in this study are based on IMGT/HLA database 3.0.0 (http:// www.ebi.ac.uk/imgt/hla, European Bioinfomatics Institute, Cambridge, UK). 1 
Matching
A substantial fraction of volunteer donors (that is, including both adult volunteers and CBUs) worldwide is still registered using HLA serological assignments and, even now, new donors are added to the worldwide pool based on serological data. Moreover, although DNA-based typing and allele matching are the established gold standards for hematopoietic SCT, registries continue to receive search requests for patients with HLA phenotypes containing serological assignments. As a consequence, a registry's matching program must still be able to compare donor-patient pairs regardless of whether their typing derives from serologic or DNA-based testing methods. The comparison should also take into account the probability that further HLA typing will turn out favorably for the patient. For example, the matching algorithm might sort serologically typed donors who are more likely to carry the same HLA alleles as the patient higher on the list.
Matching serologic Ags
The serological HLA nomenclature as defined by the 'WHO Nomenclature Committee for Factors of the HLA System' 2 contains a list of Ag designations and their relationships, which are published on the WMDA reference web site http://hla.alleles.org/wmda. These relationships (broad, split and associated Ags) reflect the refinement in the specificity of serological reagents over the years. With the overwhelming success of DNA-based typing technology, the official serological nomenclature has been unchanged for a number of years now and is unlikely to be updated with new Ags in the foreseeable future.
When comparing two serological assignments, a matching program should properly discriminate and prioritize the following cases of potential matches:
For a patient with an associated Ag (for example, A203), donors with this Ag (A203) should precede donors typed with the less specific assignment (A2) on a search report. For a patient with a split Ag (for example, A23), donors with this Ag (A23) should precede donors typed with the broad assignment (A9). For a patient with a broad assignment, there is no need to discriminate among donors with various subtypes of that Ag. For example, for a patient typed as B16, there is no need to discriminate among donors typed as B16 or B38 or B39 or B3901 or B3902; the same is true for a patient carrying B39 and donors with B39 or B3901 or B3902.
Matching allelic assignments
The allelic HLA nomenclature and the nucleotide sequences of the alleles is maintained and quarterly updated on the Internet under the following addresses: http://hla. alleles.org and http://www.ebi.ac.uk/imgt/hla. For defining an allele level match, the following concepts are currently considered:
Matching the complete nucleotide sequences (exons and introns) of an HLA gene: This corresponds to matching all of the digits in a current allele name. Matching the amino acid sequences of the proteins encoded by the alleles: This corresponds to matching the first two fields ('four digits') of the allele names (as long as both alleles are expressed as functional proteins on the cell surface). Matching the 'Ag Recognition Site' (ARS): This means regarding as matches expressed alleles that encode identical amino acid sequences in the regions interacting with the presented Ag and the T-cell receptor. This corresponds to alleles with exons specifying the same amino acid sequence for the ARS. For class I alleles, this includes the sequence specified by exons 2 and 3 and for class II alleles, the sequence specified by exon 2 only. Recent changes in the HLA nomenclature contain designations for all groups of alleles with identical ARS (for example, A*01:01P).
All three categories imply a serological match. Strictly speaking, only the first one defines a real allele match but in practice most current implementations of molecular matching programs use the third definition. This is due to the identification of the HLA protein, not the HLA gene, as the target for allorecognition; the lack of evidence for detrimental effects of differences outside the ARS; and the simpler and more efficient typing strategies sufficient for the third definition. However, based on linkage considerations, registries considering the importance of matching across the entire MHC (that is, matching non-HLA genes within the complex) may prefer matching based on the first definition.
Matching with allelic ambiguities
The typing result of an individual's HLA genes is often not determined unambiguously on the allele level. Allelic ambiguities occur in the form of multiple allele codes (for example, A*02:WN corresponding to A*02:02 or A*02:04 or A*02:05:01 or A*02:05:02 or A*02:05:03), shortened allele codes (for example, A*02:05 derived from A*02:05:01 and/or A*02:05:02 and/or A*02:05:03) or serologic assignments (for example, A2). 3 Whenever serological as well as DNA-based assignments are available for an individual, the serological data can be used to refine the typing. For example, if an individual is recorded as B*40:XX, 15:XX and B60, 75, the long list of phenotypes can substantially be shortened by restricting it to those alleles that are compatible with the given serology. However, because of the limitations in HLA-C serologic typing reagents, it is common practice to ignore serological HLA-C typing whenever DNA-based results are available, especially if the serology only includes a single Ag.
When matching two phenotypes in which one or both contain allelic ambiguities, all possibly present genotypes of both donor and patient should be compared and the best possible classification concerning the matching category or the count of proven mismatches should be used. It may be beneficial to discard very unlikely combinations in this process, for example, by using allele or, even better, haplotype frequencies of the populations of the donor and the patient or by considering a list of common and well-documented alleles. 4 Related technical details and an illustrating example are provided in section B of the technical Appendix.
Comparing serological and DNA-based HLA types (mapping) The coexistence of the serologic and the allelic HLA nomenclatures caused by the usage of different typing methodologies is a daily challenge. The utilization of several typing results obtained with different technologies for the same individual, the comparison of patient and donor assignments or the comparison of the suitability of several donor phenotypes based on different typing technologies are non-trivial tasks. To be able to compare assignments obtained by different methodologies, a mapping between the two nomenclatures has to be performed:
Mapping alleles to Ags is useful for the generation of search determinants. The vast majority of alleles and a substantial amount of unresolved allele alternatives (that is, designated by 'multiple allele codes') can be mapped to exactly one Ag, although some alleles such as B*07:31 or ambiguous typings such as B*50:AB (that is, B*50:01:01 or B*50:01:02 or B*50:02) have to be mapped to more than one Ag. By doing that, the huge number of alleles can be reduced to a small number of Ags that can be used for performing a fast Ag-based donor preselection. Mapping Ags to alleles is useful for HLA matching algorithms. Generally each Ag can be mapped to a set of alleles, that is, can be interpreted as alternative allele assignments similar to 'multiple allele codes'. This mapping allows the algorithms to perform a purely allele-based matching and permits the generation of integrated match lists containing donors typed by different methodologies.
It is possible to use the first approach to match a donor typed by serology with a patient typed by DNA or vice versa. However, it is less efficient than the second approach as soon as DNA-based typing at low or intermediate resolution is involved, especially when also mixed with serological data for the same locus. Therefore, the general matching procedure described in the technical Appendix requires mapping of Ags to alleles. For this purpose, the relationship data published on the WMDA-designated reference web site http://hla. alleles.org/wmda should be used.
Evaluating mismatches at a single locus
Interpretation rules for the HLA phenotype at a single locus Before one can compare patient and donor phenotypes at an HLA locus, some rules must be formulated regarding how to deal with a number of practical coding issues:
Alleles with expression-level suffixes 'N' (non-expressed), 'S' (secreted/soluble) or 'C' (cytoplasmic) should be considered as absent for matching purposes. For example, a volunteer typed as A*01:04N, A*66:01 should be considered as an A*66:01 homozygote. All other alleles, including those with the suffixes 'L' (low), 'A' (aberrant) and 'Q' (questionable) should be treated as expressed alleles. If a phenotype has only one antigenic or allelic assignment (for example, A1,À or A*01:02,À) the individual should be treated in the same way as one who is homozygous for the given/expressed assignment. If one serological assignment includes the other (for example, A9, 23), the narrower assignment should be disregarded for the matching routine. Although not used in matching, both assignments should be shown on the search report.
Direction and counting of mismatches
The first step in the matching process is to count the number of mismatches. This starts with a pairwise comparison of the HLA assignments of the donor and the patient in host-versus-graft (HvG) and graft-versus-host (GvH) directions separately. If an individual is homozygous (or being treated as homozygous), the single Ag/ allele is only considered once in counting the mismatches (that is, A*01:02,-patient and A*03:02,-donor would have one allelic mismatch, not two). Whenever homozygosity is involved, the number of mismatches in HvG and GvH directions may differ. There are various options on how to digest differing counts into a final match grade. Using the maximum of both values is a safe approach, but others may be considered upon careful discussion between the medical and technical experts. Details are worked out in section B of the technical Appendix.
Prioritizing mismatched donors
Allelic variants with only silent substitutions and/or differences in non-coding regions are regarded as identical as long as both variants are expressed. Moreover, it is customary not to differentiate between allelic variants with differences outside the Ag recognition site (that is, exons 2 and 3 for HLA class I and exon 2 for HLA class II).
Earlier studies have speculated that mismatches at the serological level are worse than those only detectable with DNA-based assay methods, 5, 6 but this has not been confirmed in larger and more recent studies. [7] [8] [9] Therefore, ranking of mismatched donors in hematopoietic SCT based on the serological relationships should not be carried out as long as other relevant criteria can be applied. However, in cases in which such a prioritization is desired, the order of donors should be the following:
Allelic variants indistinguishable by serological methods. Mismatched Ags associated with the same 'broader' Ag, for example, B3901 donor for a B3902 patient or A203 for an A210 patient. Mismatched Ags that are splits of the same broad Ag, for example, B38 donor for a B39 patient. In such cases, there is no differential ranking of associated Ags; that is, for a patient with B38, donors typed as B39, B3901 or B3902 should be treated as identical in the ranking order. All other ('broad') mismatches, that is, those in which the Ags have no broad/split/associated relationship with the patient's assignment. Examples are an A1 donor for an A2 patient or a B7 donor for a B52 patient.
In the last three cases, allelic differences corresponding to each of the serologically characterized differences have to be handled consistently according to the correspondence tables between serologic and allelic assignments described in the literature. 10, 11 See section A of the technical Appendix for more details, in particular on alleles whose serological correspondence is only insufficiently or ambiguously characterized.
Evaluating mismatches at multiple loci
It is acceptable to restrict matching to only three or four HLA loci and also to match one or more loci only using low-resolution DNA assignments. On this basis, donor lists should primarily be sorted according to the number of mismatches. As it is intuitively expected by many users, it is customary to sort the donors within equal counts of mismatches according to the mismatching categories described in the section above. However, unless supported by clinical data, we explicitly do not recommend to do so.
If the donor and/or the patient are not yet typed at high resolution, donors may be sorted according to their probability not to reveal any (additional) mismatches when extended typing is performed. Such probabilities may be estimated using the allele or haplotype frequencies of the population of the donors and patients and, as far as possible, should be validated with retrospective and prospective data. We refer to section B of the technical Appendix for more details.
Organizing and prioritizing donors on lists
Specifying the concrete behavior of a matching program requires a close and intensive cooperation between the transplant physicians, HLA experts and software developers. Eventually, the team has to consistently decide (1) which donors should or might appear on the list and (2) the order in which these donors appear on the list, that is, the sorting. Although the first may be intricate for some patients with unusual tissue types, the second will be relevant for the vast majority of patients in which many donor candidates enter the analysis.
Most matching programs decide which of two donors should be listed first on the basis of a 'match grade' that typically corresponds to a number or a string that can be used for sorting the list. Below we describe the considerations necessary when constructing an overall match grade from the match grades of individual loci and other criteria.
Separation of match lists
We assume that a matching program is confronted with donors who have been typed for HLA-A and HLA-B, at a minimum. We also assume that CBUs are always also typed for HLA-DR(B1). Then, we generally recommend that separate match lists are provided for adult stem cell donors and for CBUs, as the latter are chosen on the basis of HLA compatibility and total nucleated cell count and as their matching and sorting criteria differ substantially from those of adult donors.
Moreover, it is currently customary to provide separate match lists for donors that have only HLA class I assignments and those with HLA class I and class II typing data (at least HLA-DR or HLA-DRB1 at low resolution). This is performed for practical and statistical reasons:
The integration of donors with and without DR(B1) results would raise the question of at which position donors without DR(B1) assignments should be included on a search report, before or after DR(B1)-typed donors with a known HLA difference. As the length of donor lists must be limited, there is always the risk that the list may be truncated prematurely and donors who should be seriously considered are missed. For those patients lacking a matching HLA-A,B,DR(B1)-typed donor nowadays, the probability that an HLA-A,B-matched donor would turn out to be also a match for HLA-DRB1 is estimated to be approximately 1:100 (ZKRD, unpublished data). Separate listing of HLA-A,B-matched donors makes sense as those donors are typically accessed in a logically separated part of the search strategy and typing for DRB1 is usually performed before any other test on those donors.
However, we acknowledge that depending on the underlying registry data and a sophisticated solution for the ordering issue mentioned above, an integrated match list may be an equally reasonable approach.
Ranking by HLA loci An algorithm summarizing the degree of matching of individual HLA loci into an overall match grade requires decisions on how to prioritize mismatches among loci and how to weigh multiple HLA differences. The internal representation of the match grade should facilitate sorting and filtering lists of potential donors and may also differentiate between the immunological vector (HvG and/or GvH) of the differences detected.
It is quite common that certain 'primary HLA loci' are considered first in a matching process (typically, at least, HLA-A, -B and -DRB1, but probably should include HLA-C as well). The number of mismatches (overall and/ or per category) will usually be summed up for this group of loci. A preference for mismatches at certain loci may be reflected by the sequence in which the individual match grades are combined or by applying appropriate filter criteria. For example, certain loci (for example, HLA-DQB1 and HLA-DPB1) may be included in the matching at a lower priority. Whether these loci are treated individually (so that the one considered first will have absolute priority over all subsequent ones) or summarized into a match grade for 'secondary HLA loci' may depend on the local preferences.
Ranking by other criteria In the discussion above, the following ranking criteria have already been mentioned:
Separate match lists for HLA-A,B-typed donors, HLA-A,B,DR(B1)-typed donors and CBUs. HLA-related match grades including the overall HLA match grade for primary loci, the overall HLA match grade for secondary loci and the match grade for individual HLA loci. Each of these match grades can be used separately for HvG and/or GvH directions and/or condensed by using the maximum and/or the sum of the two (see section B in the technical Appendix, which is available on the Bone Marrow Transplantation website).
Moreover, there are numerous other criteria that may be considered in sorting lists of donors or CBUs:
The number of nucleated and/or CD34-positive cells is a highly relevant criterion for CBUs. Probabilities of a donor or CBU to turn out to be suitable according to certain criteria: * Probability to be a 6/6 and 5/6 (or 8/8 and 7/8 or even 10/10 and 9/10) match. CBU matches may also consider 4/6 matched units. * Probability to be a 2/2 or 1/2 match at a certain locus. The resolution and loci used may vary for donors and CBUs. Such probability calculations can be made using haplotype frequencies or, less precisely, using allele frequencies. In serology, the number of broad assignments may be used as an indicator for a lower probability that a donor will turn out to be a match.
For HLA loci initially only matched at low resolution, a high-resolution matching may be used as an additional search criterion of lower priority. Weight for adult donors Gender Age for adult donors Storage time and/or collection date for CBUs CMV status ABO blood group and rhesus factor Each of the elements enumerated above can be used in the construction of an overall match grade. Practically, a computer program would do that by combining elements representing the information in a way suitable for a standard sorting algorithm. For the presentation on a match list to the transplant center, the internal match grade usually has to be simplified and translated into a form that is easier to read and is understood by the users.
To reflect practical or clinical needs, match lists may be pruned by applying user-defined filtering criteria. These may depend on the diagnosis, the urgency and other parameters of the patient as well as the size and composition of the pool of relevant donors. Potential filter criteria include the number and localization of mismatches accepted as well as the CMV status and gender of the donor.
Validation
Finally, any implementation of a matching algorithm has to be validated thoroughly before being used in practice so that conceptual deficiencies and implementation errors are identified. The Information Technology Working Group of the WMDA is working on matching validation sets that will provide defined matching trials and their expected outcomes. 12 The validation procedure has to consider the following aspects:
Completeness: For performance reasons, it is not possible to perform a full match grade evaluation of all donors for a patient in databases of large registries. Usually, the time-consuming evaluation is restricted to relevant donors only, identified by an efficient preselection phase using Ag-based search determinants. It is important not to miss any relevant donor in such a filter.
Sensitivity: With regard to single patient/donor evaluations, all antigenic and allelic differences must be reliably detected by the algorithm. All nuances of the HLA nomenclature and both HvG and GvH vectors have to be addressed correctly. Prognostic matching: Allele and/or haplotype frequencies can be used to predict the likelihood that any donor with incomplete or lower resolution HLA assignments will turn out to be a match or a mismatch. The quality of such prognoses and also of the underlying population data used to predict a match (that is, allele and haplotype frequencies) has to be reviewed using appropriate retrospective and/or prospective studies. For the time being, this is beyond the scope of this framework as there are no standardized sets of haplotype frequencies available.
Hence, it is recommended to apply any matching implementation to the WMDA matching validation sets and compare the outcome with regard to completeness and sensitivity with the references. This validation should be performed as an automated standard test that can easily be repeated when the programs are updated. In addition, it is advisable to compare the results of a new matching procedure with the results of an already well-established algorithm, for example, the online matching program of Bone Marrow Donors Worldwide (BMDW) 13 applied to the same data set. Any software validation must include the 'man-machineinterface', which in our case is the way the match lists are presented on screen or paper to the end user in the HLA laboratory and transplant center. The registry must ensure that the people interpreting its match lists understand the information given for each donor as well as the logic behind the selection, sorting and filtering of the donors presented. This is a prerequisite for allowing them to customize the donor selection based on center-specific protocols or the needs of an individual patient.
All aspects of a matching system should be regularly reviewed and updated as relevant new information on donor selection criteria becomes available.
Summary
The algorithm used to select a subset of potentially matched hematopoietic stem cell donors and then to order those donors for presentation on a search report is the cornerstone of any registry. These recommendations will assist registries in developing a matching program aimed at identifying all potentially suitable donors for any searching patient. The recommendations also guide the presentation of these donors in suitably sorted lists to aid transplant centers in rapidly identifying the best match for their patients.
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